Drug Trial Radar · NCT05852431
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
369
Actual
Start
Jun 15, 2023
Primary completion
Jul 7, 2025
Study completion Apr 9, 2026
Sponsor
- Lead sponsor
- 89bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.
Conditions
- Severe Hypertriglyceridemia
Interventions
PegozaferminDrug
Subcutaneous injection
PlaceboDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in fasting TGTime frame: 26 weeks
Locations
177 sites in 20 countries. Site status is shown where the registry gives one.
89bio Clinical Study Site
Chandler, Arizona
89bio Clinical Study Site
Peoria, Arizona
89Bio Clinical Study Site
Tucson, Arizona
89bio Clinical Study Site
Conway, Arkansas
89bio Clinical Study Site
Jonesboro, Arkansas
89bio Clinical Study Site
Little Rock, Arkansas
89bio Clinical Trial Site
Huntington Park, California
89Bio Clinical Study Site
Long Beach, California
89bio Clinical Study Site
Los Angeles, California
89bio Clinical Trial Site
Northridge, California
89bio Clinical Trial Site
Panorama City, California
89bio Clinical Study Site
Santa Ana, California
89bio Clinical Trial Site
Santa Ana, California
89bio Clinical Study Site
Thousand Oaks, California
89Bio Clinical Study Site
Tustin, California
89bio Clinical Study Site
Wheat Ridge, Colorado
89bio Clinical Trial Site
Wheat Ridge, Colorado
89bio Clinical Study Site
Bridgeport, Connecticut
89Bio Clinical Study Site
Clearwater, Florida
89bio Clinical Study Site
Clearwater, Florida
89bio Clinical Study Site
Hialeah Gardens, Florida
89Bio Clinical Study Site
Homestead, Florida
89Bio Clinical Study Site
Miami Lakes, Florida
89bio Clinical Study Site
Miramar, Florida
89Bio Clinical Study Site
Orlando, Florida
89bio Clinical Study Site
Panama City, Florida
89bio Clinical Trial Site
Port Orange, Florida
89Bio Clinical Study Site
Tampa, Florida
89bio Clinical Study Site
Atlanta, Georgia
89Bio Clinical Study Site
Columbus, Georgia
89Bio Clinical Study Site
Lawrenceville, Georgia
89Bio Clinical Study Site
Chicago, Illinois
89bio Clinical Study Site
West Des Moines, Iowa
89Bio Clinical Study Site
Wichita, Kansas
89Bio Clinical Study Site
Marrero, Louisiana
89bio Clinical Trial Site
Shreveport, Louisiana
89Bio Clinical Study Site
Oxon Hill, Maryland
89bio Clinical Study Site
Flint, Michigan
89bio Clinical Trial Site
Kansas City, Missouri
89bio Clinical Study Site
St Louis, Missouri
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.